ARTICLE | Clinical News
Guselkumab regulatory update
November 22, 2016 12:39 AM UTC
Johnson & Johnson’s Janssen Research & Development LLC unit submitted a BLA to FDA for guselkumab to treat moderate to severe plaque psoriasis. The submission includes data from the Phase III VOYAGE 1 trial (see BioCentury, Oct. 10). MorphoSys said it received an undisclosed milestone payment triggered by the BLA submission...
BCIQ Target Profiles